Sustained-Release Formulations of Topiramate
Supernus Pharmaceuticals, Inc.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 7 of these applications claim priority to application 60/859,502, filed Nov 17, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,877,248 | Sustained-Release Formulations of Topiramate In force · Medium confidence | Supernus Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 8,992,989 | Sustained-Release Formulations of Topiramate In force · Medium confidence | Supernus Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 9,549,940 | Sustained-Release Formulations of Topiramate In force · Medium confidence | Supernus Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 9,555,004 | Sustained-Release Formulations of Topiramate In force · Medium confidence | Supernus Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 9,622,983 | Sustained-Release Formulations of Topiramate In force · Medium confidence | Supernus Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 10,314,790 | Sustained-Release Formulations of Topiramate In force · Medium confidence | Supernus Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 8,298,576 | Sustained-Release Formulations of Topiramate In force · High confidence | Supernus Pharmaceuticals, Inc. | In force | High confidence |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.